Radiation therapy for stage I and II testicular seminoma: Changes in the treatment policy for the prescribed dose

Background: We set out to review treatment policy, survival rate and acute and late sequelae of histologically confirmed seminoma patients who underwe nt orchiectomy and radiation therapy Materials and Methods: Thirty patients with testicular seminoma were investigated. The follow-rip ranged from 1-2 0 years, with a median of 8.6 years. There were 23 patients with Stage I, s ix with Stage IIA and one with Stage IIB of the disease. All patients were treated with orchiectomy followed by iliac and paraaortic irradiation (medi an dose: 3900cGy for Stage I and 4000 cGy for Stage II patients). Up to 198 6 the median total nose was 40Gy, and this dose was administered to sixteen patients. After that, fourteen patients received a total dose of 32Gy. Res ults: For patients with Stage I and Stage II, 5- year disease-free survival rate was 100%. Twenty-three patients experienced certain acute reactions o r side effects and all became well after radiation therapy however, almost no patients showed severe late complications. Conclusion: In our study, rad ical orchiectomy and postoperative irradiation of iliac and paraaortic lymp haticus give goon results for patients with Stage I and II testicular semin oma.